

POST-ACUTE SEQUELAE AND ADAPTIVE IMMUNE RESPONSES IN PEOPLE LIVING WITH HIV RECOVERING FROM SARS-COV-2 INFECTION

Michael J. Peluso,¹ Matthew A. Spinelli,¹ Tyler-Marie Deveau,² Carrie A. Forman,¹ Sadie E. Munter,² Sujata Mathur,³ Alex F. Tang,¹ Scott Lu,³ Sarah A. Goldberg,³ Mireya I. Arreguin,¹ Rebecca Hoh,¹ Jessica Y. Chen,¹ Enrique O. Martinez,¹ Ahmed Chenna,⁴ John W. Winslow,⁴ Christos J. Petropoulos,⁴ Alessandro Sette,^{5,6} Daniella Weiskopf,⁵ Nitasha Kumar,² Kara L. Lynch,⁷ Peter W. Hunt,² Matthew S. Durstenfeld,⁸ Priscilla Y. Hsue,⁸ J. Daniel Kelly,³ Jeffrey N. Martin,³ David V. Glidden,³ Monica Gandhi,¹ Steven G. Deeks,¹ Rachel L. Rutishauser^{2*}, Timothy J. Henrich^{2*}

1 Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, CA, USA

2 Division of Experimental Medicine, University of California, San Francisco, CA, USA

3 Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA

4 Monogram Biosciences, South San Francisco, CA, USA

5 Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA, USA

6 Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego (UCSD), La Jolla, CA, USA

7 Division of Laboratory Medicine, University of California, San Francisco, CA, USA

8 Division of Cardiology, University of California, San Francisco, CA, USA

* Equal contribution

26 To whom correspondence

27 should be addressed:

Michael J. Peluso, MD

28

Assistant Professor of Medicine

29

Division of HIV, Infectious Diseases, and Global Medicine

30

1001 Potrero Avenue

31

San Francisco, CA 94110

32

P: 415-476-4082 ext 119

33

E: michael.peluso@ucsf.edu

34

35 Keywords: HIV, SARS-CoV-2, COVID-19, immune response, post-acute sequelae of SARS-CoV-2
36 (PASC), long COVID

37

38

39

10 **ABSTRACT**

11 Background: Limited data are available on the long-term clinical and immunologic consequences of
12 SARS-CoV-2 infection in people with HIV (PWH).

13
14 Methods: We measured SARS-CoV-2 specific humoral and cellular immune responses in people with
15 and without HIV recovering from COVID-19 (n=39 and n=43, respectively) using binding antibody,
16 surrogate virus neutralization, intracellular cytokine staining, and inflammatory marker assays. We
17 identified individuals experiencing symptomatic post-acute sequelae of SARS-CoV-2 infection
18 (PASC) and evaluated immunologic parameters. We used linear regression and generalized linear
19 models to examine differences by HIV status in the magnitude of inflammatory and virus-specific
20 antibody and T cell responses, as well as differences in the prevalence of PASC.

21
22 Results: Among PWH, we found broadly similar SARS-CoV-2-specific antibody and T cell immune
23 responses as compared with a well-matched group of HIV-negative individuals. PWH had 70% lower
24 relative levels of SARS-CoV-2 specific memory CD8⁺ T cells (p=0.007) and 53% higher relative
25 levels of PD-1⁺ SARS-CoV-2 specific CD4⁺ T cells (p=0.007). Higher CD4/CD8 ratio was associated
26 with lower PD-1 expression on SARS-CoV-2 specific CD8⁺ T cells (0.34-fold effect, p=0.02). HIV
27 status was strongly associated with PASC (odds ratio 4.01, p=0.008), and the proportion of PD-1⁺
28 CD4⁺ T cells and levels of certain inflammatory markers (IL-6, TNF-alpha, and IP-10) were
29 associated with persistent symptoms.

30
31 Conclusions: We identified potentially important differences in SARS-CoV-2-specific CD4⁺ and CD8⁺
32 T cells that might have implications for long-term immunity conferred by natural infection. HIV status
33 strongly predicted the presence of PASC. Larger and more detailed studies of PASC in PWH are
34 urgently needed.

35 BACKGROUND

36 As the SARS-CoV-2 pandemic continues, its intersection with the ongoing HIV pandemic has gained
37 increased attention [1]. While studies conducted early in the course of the pandemic did not show
38 differences in outcomes of acute COVID-19 associated with HIV status [2–4], larger and more
39 carefully designed studies support a growing consensus that people with HIV (PWH) are at higher
40 risk for adverse outcomes [5–9]. In addition, the SARS-CoV-2 pandemic has caused massive
41 disruption to systems of HIV care, potentially affecting access to care and antiretroviral therapy (ART)
42 [10–13]. Data on SARS-CoV-2-specific adaptive immune responses in PWH compared with HIV-
43 negative individuals remain sparse, with one recent study showing less robust immune responses
44 among PWH [14] but another [15] suggesting similar responses. Furthermore, there is growing
45 recognition of the clinical burden of post-acute sequelae of SARS-CoV-2 infection (PASC, including
46 “long COVID”) [16], but this condition remains poorly understood, especially in PWH.

47
48 While the mechanisms underlying PASC have yet to be fully delineated, early studies have suggested
49 that a combination of factors might contribute. These include innate and adaptive immune
50 dysregulation [17–20], autoimmunity [21–23], human herpes virus reactivation [24], and
51 microvascular dysfunction [25,26], among others [24]. Certain sociodemographic factors (e.g., income
52 status, access to care) [27,28] and a greater number and/or certain types of medical comorbidities
53 (e.g., obesity, diabetes mellitus, pre-existing cardiovascular or neurologic disease) [27,29,30] may
54 also increase the likelihood of an individual developing PASC. Higher prevalence of such factors
55 among PWH [31,32], along with differences in immune responses to SARS-CoV-2 [14,15] and
56 chronic inflammation and immune dysregulation even in the presence of antiretroviral therapy [33–
57 39], may make PWH selectively vulnerable to developing persistent COVID-19-attributed symptoms
58 following SARS-CoV-2 infection. For these reasons, examination of PASC in PWH is urgently needed
59 [40].

0
1 In this study, we sought to characterize SARS-CoV-2 specific immune responses and the presence of
2 persistent symptoms in a cohort of PWH with a history of COVID-19 prior to the availability of
3 vaccination in comparison to a similar group of HIV-negative individuals recovering from COVID-19.
4 We hypothesized that PASC would be more prevalent among PWH and that this would be driven by
5 reduced SARS-CoV-2 specific immune responses and increased indices of systemic inflammation
6 among this population.

7 8 **METHODS**

9 *Informed consent*

10 The study was approved by the Institutional Review Board at the University of California, San
11 Francisco (UCSF). All participants provided written informed consent.

12 *Participants*

13 Volunteers were enrolled into the Long-term Impact of Infection with Novel Coronavirus (LIINC)
14 COVID-19 recovery cohort at UCSF (NCT 04362150). Study procedures are described in detail
15 elsewhere [41,42]. Briefly, participants with a prior positive nucleic acid amplification test confirming
16 SARS-CoV-2 infection were enrolled ≥ 21 days following symptom onset. Recruitment occurred
17 through a combination of self- and clinician referrals; all PWH testing positive for SARS-CoV-2 at two
18 UCSF-based HIV clinics were notified of the study and invited to participate. At each study visit,
19 participants completed a structured interview with a research coordinator in which they provided
20 clinical data regarding prior and current COVID-19 attributed symptoms, medical and HIV history, and
21 quality of life.

14 For the current study, we selected all PWH who enrolled prior to the receipt of a SARS-CoV-2
15 vaccine (n=39) and compared them with HIV-negative individuals (n=43) with a similar distribution of
16 key variables demonstrated to be important in determination of the SARS-CoV-2 immune responses
17 in our cohort [17,43–45]: age, sex, hospitalization during COVID-19, and time since infection. We
18 assessed their immunologic parameters and symptoms at the time point closest to 16 weeks post-
19 infection (median 112 days [IQR: 91-129]).

21 *Clinical assessment of PASC*

22 Our methodology for assessing PASC in the cohort is described in detail elsewhere [42]. At each
23 study visit, we tabulate responses to questions regarding the presence of 32 somatic symptoms
24 derived from the U.S. Centers for Disease Control (CDC) list of COVID-19 symptoms [46] and the
25 Patient Health Questionnaire Somatic Symptom Scale [47]. Importantly, symptoms are only
26 considered as related to COVID-19 if they are new or worsened since the time of initial SARS-CoV-2
27 infection; stable, chronic symptoms that pre-dated SARS-CoV-2 infection are not included in the
28 PASC definition.

30 For the primary analysis, we defined PASC as any COVID-19 attributed symptom that was present
31 during a study visit >6 weeks following SARS-CoV-2 infection; this definition was selected because it
32 is consistent with prior work and consensus definitions [48,49]. We conducted further sensitivity
33 analyses using a stricter definition of PASC as 3 or more symptoms at this timepoint, comparing this
34 group to those with fewer than 3 symptoms and to those with no symptoms.

36 *Biospecimen isolation*

37 Peripheral blood mononuclear cells (PBMCs), plasma and serum were obtained from participants and
38 cryopreserved prior to testing. PBMCs were isolated using Ficol-Paque in SeptMate Tubes. PBMCs

were frozen in heat inactivated FBS and 10% dimethyl sulfoxide (DMSO) and stored in liquid nitrogen.

Antibody assays

Virus-specific antibody responses were measured the Pylon COVID-19 total antibody assay (ET Health) and a validated surrogate virus neutralization test (sVNT) [50]. The sVNT measures competitive inhibition of the interaction of the original SARS-CoV-2 RBD and angiotensin-converting enzyme 2 (ACE-2). The lower limit of detection was a sVNT reciprocal titer <10 and anti-RBD IgG <10 relative fluorescence units.

T cell responses by Intracellular Cytokine Staining (ICS)

We performed ICS as previously described [44] with the following modifications. After thawing, PBMCs were rested overnight at 37°C at a concentration of 1×10^6 PBMC per well in RPMI plus 10% FBS, penicillin, streptomycin, and L-glutamine (R10). The following day, PBMCs were cultured for 18 hours at 37°C in 96-well U-bottom plates at 1×10^6 PBMC per well in R10 in the presence of either SARS-CoV-2 peptide megapools (described in [51]; [1 µg/ml/peptide]), or 0.25- 1×10^6 PBMC per well with CD3/CD28 beads (Immunocult, STEMCELL Technologies) as a positive control or equimolar DMSO as negative control. Two previously-described peptide megapools containing SARS-CoV-2-derived peptides experimentally determined to be recognized by CD4+ or CD8+ T cells were used for peptide stimulation (CD4-E with 280 and CD8-E with 454 T cell epitopes) [51]. All conditions were in the presence of brefeldin A (Thermo Fisher), monensin (Thermo Fisher) and anti-CD107a. After an 18-hour incubation, cells were washed and surface markers were stained for 15 min at room temp in the dark. Following surface staining, cells were washed twice with PBS and then fixed/permeabilized (BD Cytofix/Cytoperm) for 20 min at 4°C in the dark. Cells were then washed twice with perm wash buffer (BD Perm/Wash) and stained with intracellular antibodies for 30min at 4°C in the dark. All

34 samples were acquired on a BD LSR-II analyzer and analyzed with FlowJo X software. The flow
35 cytometric gating strategy is shown in Supplementary Figure 1.

36 37 *Markers of inflammation*

38 In a subset of participants with additional specimens available, the fully automated HD-X Simoa
39 platform was used to measure biomarkers in blood plasma including monocyte chemoattractant
40 protein 1 (MCP-1), Cytokine 3-PlexA (IL-6, IL-10, TNF α), interferon gamma-induced protein-10 (IP-
41 10), and interferon-gamma (IFN γ). Samples were assayed blinded with respect to associated patient
42 and clinical information. Assay performance was consistent with the manufacturer's specifications.

43 44 *Statistical methods*

45 We used descriptive statistics to characterize the cohort. For the comparison of humoral responses,
46 we first log-transformed sVNT and total antibody values as relative differences are more clinically
47 meaningful than absolute differences, and to satisfy assumptions of a normal distribution. We then
48 used linear regression models to examine differences in magnitude of humoral models by HIV status,
49 adjusting for days since onset of known SARS-CoV-2 infection, age, sex at birth, history of
50 hospitalization for SARS-CoV-2 infection, and the primary indicator for the analysis, HIV status.
51 Differences and 95% confidence intervals (CI) are presented as fold-changes in the geometric mean.
52 Among PWH, CD4/CD8 ratio was then added to the model as an additional covariate to examine if
53 CD4/CD8 ratio was associated with magnitude of responses among PWH. To examine percent
54 differences in cellular immune responses by HIV status, we used generalized linear models from the
55 binomial distribution with bootstrapped standard errors and adjusted for the same potential
56 confounders as above. To examine differences in relative mean inflammatory markers by HIV-status,
57 we fit linear regression models following log-transformation of the individual inflammatory markers. To

examine differences in the experience of PASC by HIV status, we used logistic regression adjusting for the same potential confounders.

RESULTS

Participants

All participants were diagnosed with COVID-19 by nucleic acid amplification (NAA) testing between March and December 2020 (pre-Delta and Omicron) and none had received a SARS-CoV-2 vaccine prior to specimen collection. The groups were similar in terms of age, sex, and race/ethnicity (Table 1). The vast majority of PWH in the study were men, reflecting the demographics of the San Francisco Bay Area HIV epidemic [52]. While most participants were generally healthy, those with HIV more commonly reported concurrent medical comorbidities including heart and lung disease. The majority of participants were managed as outpatients during their acute COVID-19 illness. Among the minority who were hospitalized, all required supplemental oxygenation and only one participant in each group required mechanical ventilation. No participant reported receiving SARS-CoV-2-specific treatments during their acute illness.

The median time between COVID-19 symptom onset and research assessment was 117 (85-128) days for PWH and 111 (94-131) days for HIV-negative individuals ($p=0.58$; Table 2). Initial illness severity was similar between both groups (13% vs 17% hospitalized, $p=0.41$) Participants reported a wide array of symptoms attributed to COVID-19 at the time of PASC assessment (Table 2). There were similarities in post-acute symptoms reported among both groups, but a larger proportion of PWH reported certain symptoms such as fatigue, gastrointestinal and certain neurocognitive symptoms, and issues with sleep.

SARS-CoV-2-specific antibody responses

13 Antibody responses were similar between people with and without HIV infection. In models
14 incorporating HIV status, days since infection, age, sex, and prior hospitalization during SARS-CoV-2
15 infection (yes vs. no), HIV status was not a predictor of humoral responses as measured by SARS-
16 CoV-2-specific antibody binding (1.31-fold higher; 95%CI: 0.70-2.46; $p=0.40$; Fig. 1a) and surrogate
17 virus neutralization testing (1.01-fold higher; 95% CI: 0.63-1.63; $p=0.95$; Fig. 1b). Hospitalization
18 during acute COVID-19 was associated with 4.29-fold higher geometric mean titers of binding
19 antibodies (95% CI:1.74-10.57; $p=0.002$) and 2.57-fold higher titers of surrogate viral neutralization
20 testing (95% CI: 1.33-4.98; $p=0.005$).

21 22 *SARS-CoV-2 specific T cell responses*

23 We measured SARS-CoV-2-specific memory T cells by intracellular cytokine staining (ICS) after
24 stimulation with peptide megapools containing predicated SARS-CoV-2 CD4+ (CD4-E) or CD8+
25 (CD8-E) T cell epitopes, as described [51]. In models incorporating days since infection, age, sex,
26 and prior hospitalization during SARS-CoV-2 infection, HIV status was not a predictor of the
27 magnitude of interferon gamma (IFN γ)-producing SARS-CoV-2-specific memory CD4+ T cell
28 responses (1.13-fold higher; 95%CI: 0.76-1.71; $p=0.53$; median: 0.070% vs. 0.068%; Fig. 1c).
29 However, PWH had 70% lower relative levels of SARS-CoV-2-specific memory CD8+ T cells (0.30-
30 fold; 95% CI: 0.12-0.72; $p=0.007$; median: 0.034% vs. 0.016%; Fig. 1c.).

31
32 PWH exhibited higher levels of PD-1 expression on SARS-CoV-2-specific memory CD4+ T cells in
33 adjusted regression analyses (1.53-fold higher; 95% CI: 1.12-2.10; $p=0.007$; median: 57.1% vs.
34 65.0%; Fig. 1d;), but no significant differences in PD-1 expression on SARS-CoV-2 specific CD8+ T
35 cells (1.21-fold higher; 95% CI: 0.75-1.94; $p=0.44$; median: 24.1% vs. 25.0%; Fig. 1d).

36 37 *Effect of CD4/CD8 ratio*

38 The ratio of CD4+ to CD8+ T cells in the peripheral blood is a marker of general immune health in
39 people with HIV [53]. Because a low CD4/CD8 ratio has been associated with reduced responses to
40 vaccination against yellow fever in PWH [54], we next examined whether the CD4/CD8 ratio was
41 associated with adaptive immune responses after infection with SARS-CoV-2 among PWH using
42 adjusted regression modeling as above with the addition of CD4/CD8 ratio as a covariate. The ratio
43 was not predictive of binding antibody levels ($p=0.30$) or surrogate virus neutralization ($p=0.61$).
44 Higher ratios were associated with 67% lower overall frequency of SARS-CoV-2 specific CD4+ T cells
45 (0.33-fold; 95% CI: 0.19-0.97; $p=0.04$) and 36% lower SARS-CoV-2 specific PD-1 expression (0.64-
46 fold 95% CI:0.57-0.97; $p=0.03$). Notably, higher CD4/CD8 ratios were also associated with 66% lower
47 PD-1 expression on SARS-CoV-2 specific CD8+ T cells (0.34-fold 95% CI: 0.13-0.87; $p=0.02$). There
48 was a nonsignificant trend toward a similar finding among HIV-negative individuals (0.70-fold; 95%
49 CI: 0.47-1.04; $p=0.08$).

51 *Relationship between antibody and T cell immune responses*

52 Similar to our prior work [43], we observed strong correlations between the binding ($r=0.33$, $p=0.008$)
53 and surrogate viral neutralization response ($r=0.33$, $p=0.007$) and between binding and surrogate viral
54 neutralization responses and SARS-CoV-2-specific CD4+ T cells ($r=0.41$, $p<0.001$ and $r=0.42$,
55 $p<0.001$, respectively).

57 *Markers of systemic inflammation*

58 PWH had higher levels of plasma markers of inflammation compared with HIV-negative comparators.
59 Among PWH, mean IL-6 levels were 1.55-fold higher (95% CI: 1.06-2.26; $p=0.02$), mean IP-10 levels
60 were 1.31-fold higher (95% CI: 1.06-1.62; $p=0.01$), and TNF α levels were 1.26-fold higher (95% CI:
61 1.08-1.47; $p=0.003$) than in HIV-negative comparators .

33 *Post-acute sequelae*

34 We found HIV status to be highly associated with the presence of PASC. In the primary analysis
35 defining PASC as any COVID-19 attributed symptom that was new or worsened since the time of
36 SARS-CoV-2 infection and present at the time of the visit, PWH had 4.01-fold higher odds of
37 reporting PASC (95% CI: 1.45-11.1; $p=0.008$), in a model controlling for time since infection,
38 hospitalization, and age. This relationship was maintained when defining PASC as 3 or more
39 symptoms in comparison to fewer than 3 symptoms (adjusted odds ratio (AOR) 2.72; 1.08-6.88;
70 $p=0.03$). PWH reported more somatic symptoms overall (median 3 [IQR 1-6] versus median 1 [IQR 0-
71 5], $p=0.02$), and in a model including time since infection, hospitalization, sex, and age, those with
72 HIV had a 1.91-fold higher number of individual PASC symptoms than those without HIV ($p=0.02$).

73
74 Antibody and T cell immune responses did not correlate with PASC within the cohort (Fig. 2a-d).
75 However, in models adjusting for HIV status, higher PD-1 expression on total non-naive CD4+ T cells,
76 but not CD8+ T cells, was independently predictive of PASC when controlling for HIV-status (Fig. 2e-
77 f). Each 10% decrease in PD-1 expression was associated with 2.02 fold-higher odds of PASC (AOR
78 2.02; 95% CI: 1.03-3.96; $p=0.04$).

79
30 We found that some inflammatory markers were associated with increased odds of PASC (Fig. 3a-e).
31 After adjusting for HIV status, the odds of PASC increased 1.18-fold for each 10% increase in IP-10
32 (AOR 1.18; 95% CI:1.01-1.38; $p=0.04$); and 1.10-fold for each 10% increase in IL-6 (AOR 1.10; 95%
33 CI: 1.01-1.21; $p=0.04$); while there was a trend in increased PASC with higher TNF α levels (AOR
34 1.19; 95% CI: 0.98-1.46; $p=0.08$). Other plasma markers of inflammation were not associated with
35 experience of PASC, including IL-10 ($p=0.61$), interferon gamma ($p=0.73$), and MCP-1 ($p=0.93$).

36

Among PWH, there were increased odds of PASC with each 10% increase in IP-10 levels (AOR 1.06; 95% CI: 1.00-1.11; $p=0.05$), and a trend for increased PASC with higher TNF α levels (AOR 1.20; 95% CI: 0.97-1.49; $p=0.09$), but not IL-6 ($p=0.64$). This analysis was limited by the relatively small number of individuals with HIV who reported full recovery.

DISCUSSION

We found that post-acute COVID-19-attributed symptoms were common in this cohort of mostly ART-treated PWH recovering from SARS-CoV-2 infection. HIV status was strongly associated with PASC, raising concerns that this condition might be common among PWH recovering from COVID-19. Among those living with HIV, we observed broadly similar SARS-CoV-2-specific antibody and T cell immune responses as compared with a well-matched group of HIV-negative individuals, and higher levels of markers of inflammation that were also associated with PASC. Finally, we observed potentially important differences in SARS-CoV-2 specific CD4 $^{+}$ and CD8 $^{+}$ T cells that might have implications for long-term immunity conferred by natural infection. This analysis adds to the limited published data examining SARS-CoV-2-specific immune responses in PWH and underscores the need for larger and more detailed studies of PASC in this population.

An unknown proportion of people experience PASC following acute COVID-19, and there are currently massive efforts underway to understand the pathophysiology of this condition. There are limited data on PASC among PWH [55], however. One single-center study suggested that acute illness severity in PWH was significantly associated with PASC with 44% of participants experiencing at least one symptom 30 days after recovery [40], however it did not find an association between clinical parameters such as CD4 $^{+}$ T cell count, viral load, demographics or comorbidities and the presence of PASC, and did not compare PWH with HIV-negative individuals. Another retrospective study suggested that HIV was one factor that was associated with higher risk of PASC approximately

12 one year after COVID-19 diagnosis among those requiring emergency department or hospital-based
13 care [56], but the analysis was limited to 10 PWH and did not include biological measurements. While
14 our cohort is not representative of all individuals with SARS-CoV-2 infection and cannot be utilized to
15 estimate the population-level prevalence of PASC in the overall population or among PWH, the
16 observation that persistent SARS-CoV-2-attributed symptoms were highly prevalent in PWH and that
17 the adjusted odds of PASC were nearly four-fold as high as in a relatively well-matched HIV-negative
18 comparator group was striking. Further description of this condition among PWH is urgently needed,
19 including both detailed cohort descriptions and large-scale epidemiologic studies in which HIV can be
20 examined as a predictor of PASC.

21
22 There are biological reasons why PWH might be particularly predisposed to developing PASC. One
23 leading hypothesis is that PASC is driven, at least in part, by residual or ongoing inflammation
24 following SARS-CoV-2 infection [17–20]. Even with suppressive ART, HIV is a chronic inflammatory
25 condition that can be associated with complications of persistent immune activation [33–39]. If a
26 higher prevalence of PASC among PWH recovering from COVID-19 is confirmed in larger
27 epidemiologic studies, one possible explanation could be that this is driven in part by immune
28 dysregulation from SARS-CoV-2 infection compounded upon higher baseline inflammation from HIV
29 infection, which in turn could drive organ system dysfunction and the experience of somatic
30 symptoms. In addition to elevated inflammatory responses, additional factors that could potentially
31 predispose PWH to PASC include an increased frequency of autoimmune phenomena [57–59],
32 localized tissue inflammation related to mucosal and endothelial injury [31,32], and other syndemic
33 comorbidities including substance use [60,61] and metabolic disorders [62–64]. Furthermore,
34 reactivation of latent human herpes viruses, such as Epstein Barr Virus or Cytomegalovirus (CMV)
35 during acute SARS-CoV-2 infection may further perturb immune dysregulation and promote
36 inflammation. PWH tend to have higher rates of CMV infection than HIV-negative individuals and this

37 is thought to drive, in part, chronic inflammation in treated HIV and may lead to impaired CD8+ T cell
38 function. Regardless of the mechanism, our observation is of importance because it suggests that
39 PASC may be especially common in PWH and emphasizes the urgent need for larger studies of
40 PASC in this population, which are underway [65].

41
42 Data on SARS-CoV-2-specific adaptive immune responses in PWH compared with HIV-negative
43 individuals remain limited. Given the clear association between the presence of potent, durable
44 SARS-CoV-2-specific immune responses and protection from disease upon re-exposure, it is critical
45 to understand how HIV infection modulates protective antiviral immunity in PWH. Furthermore, there
46 is evidence that SARS-CoV-2 can cause chronic infection in certain immunocompromised individuals
47 [66], including those with advanced HIV infection [67], and result in viral evolution and the emergence
48 of novel variants of concern. Our findings of similar humoral immune responses between well-
49 matched groups of individuals with and without HIV infection sampled at similar time points after
50 infection add to a limited literature on adaptive immunity to natural SARS-CoV-2 infection in PWH.
51 Since the beginning of the pandemic, there has been concern that PWH might be less likely to
52 develop and maintain protective immunity. While some studies suggested lower humoral responses
53 in PWH [14], this did not appear to translate into a higher risk of re-infection in the pre-vaccine era,
54 and several other studies did not find substantial differences following natural infection in PWH on
55 suppressive ART [68–70]. Although some early data suggest that vaccine-induced immunity could be
56 less robust among PWH, it appears to be driven by the population of PWH with low CD4+ cell counts
57 [71].

58
59 Compared to antibody responses, data on cellular immune responses to SARS-CoV-2 infection in
60 PWH are much more limited. A single high-quality study to date has shown similar T cell responses
61 between PWH on suppressive ART and individuals without HIV [15]. In our rigorously matched

32 natural infection cohort, we made three key observations regarding SARS-CoV-2-specific cellular
33 immune responses in PWH compared to individuals without HIV. First, using peptide pools that
34 include optimal SARS-CoV-2 epitopes that span the proteome, we found that PWH had lower SARS-
35 CoV-2 specific CD8+ T cell responses. This difference was previously observed in non-Spike-specific
36 T cell responses in PWH and may indicate that PWH have impaired capacity to mount a protective
37 CD8+ T cell response upon SARS-CoV-2 re-infection, particularly with heterologous variants with
38 immune-evading mutations in the Spike protein. It is also possible that PWH have expansion of other
39 antigen-specific CD8+ T cells (e.g., CMV-specific) thereby diluting the SARS-CoV-2-specific pool as
70 the denominator was total non-naive CD8+ T cells. Second, after controlling for multiple clinical
71 factors including time of symptom onset, we found that SARS-CoV-2 specific CD4+ T cells had higher
72 expression of the co-inhibitory receptor PD-1, suggesting they may have impaired functionality upon
73 re-encountering infection. Alternatively, PWH may have more SARS-CoV-2 antigen exposure leading
74 to a more exhausted cell phenotype. Third, we found that a higher CD4/CD8 ratio was associated
75 with lower expression of PD-1 on SARS-CoV-2-specific CD8+ T cells among PWH. As higher
76 CD4/CD8 ratios tend to be associated with ART initiation earlier in the course of infection [72], this
77 finding adds to our understanding of how early HIV diagnosis and ART initiation is critical for
78 preserving immune responses against heterologous infections in PWH.

30 This study has several limitations. The sample size was small, as relatively few PWH were infected
31 with SARS-CoV-2 during the first year of the pandemic in our geographic area [73]. As there were few
32 PWH without PASC, we were likely underpowered to make comparisons within the PWH sub-group;
33 larger cohorts will be needed to do so. Our case definition, although potentially overly sensitive, is in
34 line with consensus case definitions [16,17] and the association between HIV status and PASC was
35 maintained in sensitivity analyses using more stringent definitions. However, given the nature of our
36 recruitment, we emphasize that the high prevalence of PASC in our study cohort should not be

37 considered to represent the population-level prevalence of this condition, which is likely much lower
38 [27]. In addition, while the groups with and without HIV infection were well-matched on key variables
39 demonstrated to be important in the immune response to SARS-CoV-2 infection and in PASC, the
40 potential for residual confounding remains. For example, data on additional clinical factors that may
41 be related to both HIV status and PASC, including comorbid mental health conditions and substance
42 use, were unavailable. We used concurrent CD4+ T cell count and CD4/CD8 ratio as markers of
43 immune reconstitution; CD4+ T cell nadir might be an important factor but we were unable to confirm
44 these values in most participants due to fragmentation of healthcare records. Regarding laboratory
45 measurements, we used a surrogate virus neutralization assay as opposed to a true neutralizing
46 assay. Our T cell assay focused on IFN γ expression to identify SARS-CoV-2-specific T cells, which
47 likely underestimates the magnitude of the total virus-specific response. We did not assess T cell
48 proliferative capacity, which may reflect the capacity of virus-specific memory T cells to respond to a
49 re-infection. Inflammatory marker data was not available on all participants, although sample
50 availability for testing was based on the timing of the specimen collection and is not expected to bias
51 the results. Finally, our population of PWH was mostly male, stable on ART, and had strong immune
52 reconstitution, and these observations should be extended to populations with less access or
53 adherence to ART or those with advanced HIV without further evidence in these subpopulations of
54 PWH.

55 Although these findings need to be confirmed in larger and more diverse cohorts, our analysis
56 provides compelling preliminary evidence that suggests an urgent need to better understand PASC
57 within people living with HIV. Better understanding the epidemiology and pathophysiology of PASC
58 within PWH may lead to targeted interventions to prevent or treat this newly identified condition
59 among this special population of interest.

10 FOOTNOTES

11 **Acknowledgements**

12 We are grateful to the study participants. We acknowledge current and former LIINC clinical study
13 team members Tamara Abualhsan, Andrea Alvarez, Melissa Buitrago, Monika Deswal, Emily
14 Fehrman, Heather Hartig, Yanel Hernandez, Marian Kerbleski, James Lombardo, Lynn Ngo, Enrique
15 Martinez Ortiz, Antonio Rodriguez, Dylan Ryder, Ruth Diaz Sanchez, Viva Tai, Cassandra Thanh,
16 Fatima Ticas, Leonel Torres, and Meghann Williams; and LIINC laboratory team members Amanda
17 Buck, Joanna Donatelli, Jill Hakim, Nikita Iyer, Owen Janson, Christopher Nixon, Isaac Thomas, and
18 Keirstinne Turcios. We thank the UCSF AIDS Specimen Bank for processing specimens and
19 maintaining the LIINC biospecimen repository. The intracellular cytokine staining assays were
20 performed in the UCSF Core Immunology Laboratory. We are grateful to Jon Oskarsson, Mary
21 Shiels, Erin Pederson, Parousha Zand, and the UCSF Ward 86 and 360 Positive Health Practices for
22 referring PWH who had COVID-19.

23 **Author Contributions**

24 MJP, JDK, JNM, SGD, and TJH designed the cohort, which was managed by RH and overseen by
25 MJP. MJP, JDK, SL, RH, JNM, and SGD designed the study instruments. MJP, SEM, AFT, MIA, and
26 RH recruited participants, coordinated research visits, administered study questionnaires, and
27 collected clinical data. CAF, SM, AFT, SAG, and JYC performed data entry and quality control and
28 addressed or adjudicated issues related to data integrity. SL cleaned the data, maintained the
29 database, and oversaw data management. Antibody measurements were performed in the laboratory
30 of KLL. NK, RLR, and TJH performed and/or oversaw the cellular immunology assays in the UCSF
31 Core Immunology Laboratory. AC, JWW, and CJP performed and oversaw the inflammatory marker
32 assays at Monogram Biosciences. DW and AS provided the SARS-CoV-2 peptide megapools. MJP,
33 MAS, TMD, SEM, DVG, RLR, and TJH performed the analyses. MJP MAS, TMD, CAF, SEM, SM,
34 SGD, RLR, and TJH drafted the manuscript with input from MSD, PYH, PWH, JFK, JNM, DVG, and

35 MG providing in depth critical review. The study was funded by grants from MAS, MG, SGD, and
36 TJH. All authors reviewed, edited, and approved the manuscript.

38 Funding

39 This work was supported by the National Institutes of Health (R01 AI141003, R01 AI158013, T32
40 AI60530, K23 AI157875, and K23 AI135037), and the UCSF/Gladstone Center for AIDS Research
41 (CFAR). MJP received funding from the UCSF Resource Allocation Program and the CFAR Rapid
42 COVID grant program. This work has been supported by NIH contract 75N93019C00065 (A.S, D.W).

44 Conflicts of Interest

45 AC, JWW, and CJP are employees of Monogram Biosciences. AS is a consultant for Gritstone Bio,
46 Flow Pharma, Arcturus Therapeutics, ImmunoScape, CellCarta, Avalia, Moderna, Fortress and
47 Repertoire. LJI has filed for patent protection for various aspects of T cell epitope and vaccine design
48 work. TJH reports grants from Merck and Co. and Bristol-Myers Squibb outside the submitted work.
49 The remaining authors have no conflicts related to the current work to report.

51 FIGURE LEGENDS

52 **Figure 1. SARS-CoV-2 specific immunologic parameters among people with and without HIV**
53 **recovering from COVID-19.** A. Total SARS-CoV-2 antibodies. B. Surrogate viral neutralization titers.
54 C. SARS-CoV-2 specific CD4+ and CD8+ T cells. D. PD1 expression on SARS-CoV-2 specific CD4+
55 and CD8+ T cells. Bars represent median and interquartile ranges.

57 **Figure 2. SARS-CoV-2 specific immune responses among people with and without PASC,**
58 **stratified by HIV status.** A. Total SARS-CoV-2 antibodies. B. Surrogate viral neutralization titers. C.
59 SARS-CoV-2 specific CD4+ T cells. D. SARS-CoV-2 specific CD8+ T cells. E. PD1 expression on

30 bulk CD4+ T cells. F. PD1 expression on bulk CD8+ T cells. Bars represent median and interquartile
31 ranges.

32
33 **Figure 3. Plasma markers of immune activation among people with and without PASC,**
34 **stratified by HIV status.** A. Interleukin-6 levels. B. TNF-alpha levels. C. Interferon-gamma levels. D.
35 IP-10 levels. E. MCP-1 levels. Bars represent median and interquartile ranges.

36 37 REFERENCES

- 38 1. Eisinger RW, Lerner AM, Fauci AS. Human Immunodeficiency Virus/AIDS in the Era of
39 Coronavirus Disease 2019: A Juxtaposition of 2 Pandemics. *The Journal of Infectious Diseases*.
40 2021; Available at: <http://dx.doi.org/10.1093/infdis/jiab114>.
- 41 2. Ho H-E, Peluso MJ, Margus C, et al. Clinical Outcomes and Immunologic Characteristics of
42 Coronavirus Disease 2019 in People With Human Immunodeficiency Virus. *J Infect Dis* **2021**;
43 223:403–408.
- 44 3. Sigel K, Swartz T, Golden E, et al. Coronavirus 2019 and People Living With Human
45 Immunodeficiency Virus: Outcomes for Hospitalized Patients in New York City. *Clin Infect Dis*
46 **2020**; 71:2933–2938.
- 47 4. Vizcarra P, Pérez-Elías MJ, Quereda C, et al. Description of COVID-19 in HIV-infected
48 individuals: a single-centre, prospective cohort. *Lancet HIV* **2020**; 7:e554–e564.
- 49 5. Bertagnolio S, Thwin S, Silva R, et al. Clinical characteristics and prognostic factors in people
50 living with HIV hospitalized with COVID-19: findings from the WHO Global Clinical Platform. In:
51 11th International AIDS Society Conference on HIV Science. 2021: 18–21.

- 32 6. Bhaskaran K, Rentsch CT, MacKenna B, et al. HIV infection and COVID-19 death: a population-
33 based cohort analysis of UK primary care data and linked national death registrations within the
34 OpenSAFELY platform. *Lancet HIV* **2021**; 8:e24–e32.
- 35 7. Tesoriero JM, Swain C-AE, Pierce JL, et al. COVID-19 Outcomes Among Persons Living With or
36 Without Diagnosed HIV Infection in New York State. *JAMA Netw Open* **2021**; 4:e2037069.
- 37 8. Rial-Crestelo D, Bisbal O, Font R, et al. Incidence and severity of SARS-CoV-2 infection in HIV-
38 infected individuals during the first year of the pandemic. *J Acquir Immune Defic Syndr* **2021**;
39 Available at: <http://dx.doi.org/10.1097/QAI.0000000000002896>.
- 30 9. Spinelli MA, Brown LB, Glidden DV, et al. SARS-CoV-2 incidence, testing rates, and severe
31 COVID-19 outcomes among people with and without HIV. *AIDS* **2021**; Publish Ahead of Print.
32 Available at: <https://journals.lww.com/10.1097/QAD.0000000000003075>.
- 33 10. Budak JZ, Scott JD, Dhanireddy S, Wood BR. The Impact of COVID-19 on HIV Care Provided
34 via Telemedicine—Past, Present, and Future. *Curr HIV/AIDS Rep* **2021**; 18:98–104.
- 35 11. Spinelli MA, Hickey MD, Glidden DV, et al. Viral suppression rates in a safety-net HIV clinic in
36 San Francisco destabilized during COVID-19. *AIDS* **2020**; 34:2328–2331.
- 37 12. Pierone G, Fusco JS, Brunet L, et al. 886. The impact of the COVID-19 pandemic on clinical
38 follow-up, monitoring and regimen discontinuation for people living with HIV in the US. *Open*
39 *Forum Infect Dis* **2021**; 8:S534–S535.
- 30 13. Galaviz KI, Shah NS, Gutierrez M, et al. Patient Experiences with Telemedicine for HIV Care
31 During the First COVID-19 Wave in Atlanta, Georgia. *AIDS Res Hum Retroviruses* **2021**;
32 Available at: <http://dx.doi.org/10.1089/AID.2021.0109>.
- 33 14. Spinelli MA, Lynch KL, Yun C, et al. SARS-CoV-2 seroprevalence, and IgG concentration and

04 pseudovirus neutralising antibody titres after infection, compared by HIV status: a matched case-
05 control observational study. *The Lancet HIV*. 2021; 8:e334–e341. Available at:
06 [http://dx.doi.org/10.1016/s2352-3018\(21\)00072-2](http://dx.doi.org/10.1016/s2352-3018(21)00072-2).

07 15. Alrubayyi A, Gea-Mallorquí E, Touizer E, et al. Characterization of humoral and SARS-CoV-2
08 specific T cell responses in people living with HIV. *Nat Commun* **2021**; 12:5839.

09 16. Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. *Nat Med* **2021**;
10 Available at: <http://dx.doi.org/10.1038/s41591-021-01283-z>.

11 17. Peluso MJ, Lu S, Tang AF, et al. Markers of Immune Activation and Inflammation in Individuals
12 With Postacute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. *J*
13 *Infect Dis* **2021**; Available at: <http://dx.doi.org/10.1093/infdis/jiab490>.

14 18. Phetsouphanh C, Darley DR, Wilson DB, et al. Immunological dysfunction persists for 8 months
15 following initial mild-to-moderate SARS-CoV-2 infection. *Nat Immunol* **2022**; :1–7.

16 19. Ong SWX, Fong S-W, Young BE, et al. Persistent Symptoms and Association With Inflammatory
17 Cytokine Signatures in Recovered Coronavirus Disease 2019 Patients. *Open Forum Infect Dis*
18 **2021**; 8:ofab156.

19 20. Bonny TS, Patel EU, Zhu X, et al. Cytokine and Chemokine Levels in Coronavirus Disease 2019
20 Convalescent Plasma. *Open Forum Infect Dis* **2021**; 8:ofaa574.

21 21. Chang SE, Feng A, Meng W, et al. New-onset IgG autoantibodies in hospitalized patients with
22 COVID-19. *Nat Commun* **2021**; 12:5417.

23 22. Song E, Chow RD, Jiang R, et al. Immunologically distinct responses occur in the CNS of
24 COVID-19 patients. *bioRxiv* **2020**; Available at: <http://dx.doi.org/10.1101/2020.09.11.293464>.

- 25 23. Seeßle J, Waterboer T, Hippchen T, et al. Persistent symptoms in adult patients one year after
26 COVID-19: a prospective cohort study. *Clin Infect Dis* **2021**; Available at:
27 <http://dx.doi.org/10.1093/cid/ciab611>.
- 28 24. Su Y, Yuan D, Chen DG, et al. Multiple Early Factors Anticipate Post-Acute COVID-19 Sequelae.
29 *Cell* **2022**; 0. Available at: [https://www.cell.com/cell/fulltext/S0092-8674\(22\)00072-](https://www.cell.com/cell/fulltext/S0092-8674(22)00072-1?dgcid=raven_jbs_aip_email)
30 [1?dgcid=raven_jbs_aip_email](https://www.cell.com/cell/fulltext/S0092-8674(22)00072-1?dgcid=raven_jbs_aip_email). Accessed 26 January 2022.
- 31 25. Pretorius E, Vlok M, Venter C, et al. Persistent clotting protein pathology in Long COVID/Post-
32 Acute Sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin.
33 *Cardiovasc Diabetol* **2021**; 20:172.
- 34 26. Wenzel J, Lampe J, Müller-Fielitz H, et al. The SARS-CoV-2 main protease Mpro causes
35 microvascular brain pathology by cleaving NEMO in brain endothelial cells. *Nat Neurosci* **2021**;
36 :1–12.
- 37 27. Ayoubkhani D, Pawelek P, Gaughan C. Technical article: Updated estimates of the prevalence of
38 post-acute symptoms among people with coronavirus (COVID-19) in the UK - Office for National
39 Statistics. Office for National Statistics, 2021. Available at:
40 [https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddisea](https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/technicalarticleupdatedestimatesoftheprevalenceofpostacutesymptomsamongpeoplewithcoronaviruscovid19intheuk/26april2020to1august2021)
41 [ses/articles/technicalarticleupdatedestimatesoftheprevalenceofpostacutesymptomsamongpeople](https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/technicalarticleupdatedestimatesoftheprevalenceofpostacutesymptomsamongpeoplewithcoronaviruscovid19intheuk/26april2020to1august2021)
42 [withcoronaviruscovid19intheuk/26april2020to1august2021](https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/technicalarticleupdatedestimatesoftheprevalenceofpostacutesymptomsamongpeoplewithcoronaviruscovid19intheuk/26april2020to1august2021). Accessed 20 September 2021.
- 43 28. Parpia AS, Martinez I, El-Sayed AM, et al. Racial disparities in COVID-19 mortality across
44 Michigan, United States. *EClinicalMedicine* **2021**; 33:100761.
- 45 29. Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of long COVID. *Nat Med* **2021**;
46 Available at: <http://dx.doi.org/10.1038/s41591-021-01292-y>.

- 17 30. Apple AC, Oddi A, Peluso MJ, et al. Risk factors and abnormal cerebrospinal fluid associate with
18 cognitive symptoms after mild COVID-19. *Ann Clin Transl Neurol* **2022**; Available at:
19 <http://dx.doi.org/10.1002/acn3.51498>.
- 20 31. Tenorio AR, Zheng Y, Bosch RJ, et al. Soluble markers of inflammation and coagulation but not
21 T-cell activation predict non--AIDS-defining morbid events during suppressive antiretroviral
22 treatment. *J Infect Dis* **2014**; 210:1248–1259.
- 23 32. Chow FC, Ma Y, Manion M, et al. Factors associated with worse cerebrovascular function in
24 aging women with and at risk for HIV. *AIDS* **2021**; 35:257–266.
- 25 33. Serrano-Villar S, Sainz T, Lee SA, et al. HIV-infected individuals with low CD4/CD8 ratio despite
26 effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation,
27 and increased risk of non-AIDS morbidity and mortality. *PLoS Pathog* **2014**; 10:e1004078.
- 28 34. Hunt PW, Sinclair E, Rodriguez B, et al. Gut epithelial barrier dysfunction and innate immune
29 activation predict mortality in treated HIV infection. *J Infect Dis* **2014**; 210:1228–1238.
- 30 35. Khoury G, Fromentin R, Solomon A, et al. Human Immunodeficiency Virus Persistence and T-
31 Cell Activation in Blood, Rectal, and Lymph Node Tissue in Human Immunodeficiency Virus-
32 Infected Individuals Receiving Suppressive Antiretroviral Therapy. *J Infect Dis* **2017**; 215:911–
33 919.
- 34 36. Burdo TH, Lo J, Abbara S, et al. Soluble CD163, a novel marker of activated macrophages, is
35 elevated and associated with noncalcified coronary plaque in HIV-infected patients. *J Infect Dis*
36 **2011**; 204:1227–1236.
- 37 37. Neuhaus J, Jacobs DR Jr, Baker JV, et al. Markers of inflammation, coagulation, and renal
38 function are elevated in adults with HIV infection. *J Infect Dis* **2010**; 201:1788–1795.

38. Méndez-Lagares G, Romero-Sánchez MC, Ruiz-Mateos E, et al. Long-term suppressive
combined antiretroviral treatment does not normalize the serum level of soluble CD14. *J Infect
Dis* **2013**; 207:1221–1225.
39. Borges ÁH, O'Connor JL, Phillips AN, et al. Factors Associated With Plasma IL-6 Levels During
HIV Infection. *J Infect Dis* **2015**; 212:585–595.
40. Pujari S, Gaikwad S, Chitalikar A, Dabhade D, Joshi K, Bele V. Long-coronavirus disease among
people living with HIV in western India: An observational study. *Immun Inflamm Dis* **2021**;
9:1037–1043.
41. Peluso MJ, Kelly JD, Lu S, et al. Rapid implementation of a cohort for the study of post-acute
sequelae of SARS-CoV-2 infection/COVID-19. *medRxiv* **2021**; Available at:
<http://dx.doi.org/10.1101/2021.03.11.21252311>.
42. Peluso MJ, Kelly JD, Lu S, et al. Persistence, Magnitude and Patterns of Post-acute Symptoms
and Quality of Life Following Onset of SARS-CoV-2 Infection: Cohort Description and
Approaches for Measurement. *Open Forum Infect Dis* **2021**; Available at:
<https://academic.oup.com/ofid/advance-article/doi/10.1093/ofid/ofab640/6472960?login=true>.
Accessed 13 January 2022.
43. Peluso MJ, Takahashi S, Hakim J, et al. SARS-CoV-2 antibody magnitude and detectability are
driven by disease severity, timing, and assay. *Sci Adv* **2021**; 7. Available at:
<http://dx.doi.org/10.1126/sciadv.abh3409>.
44. Peluso MJ, Deitchman AN, Torres L, et al. Long-term SARS-CoV-2-specific immune and
inflammatory responses in individuals recovering from COVID-19 with and without post-acute
symptoms. *Cell Rep* **2021**; :109518.

45. Peluso MJ, Sans HM, Forman CA, et al. Plasma markers of neurologic injury and systemic inflammation in individuals with self-reported neurologic post-acute sequelae of SARS-CoV-2 infection (PASC). *bioRxiv*. 2021; Available at: <http://medrxiv.org/lookup/doi/10.1101/2021.11.02.21265778>.
46. CDC. Symptoms of COVID-19. 2021. Available at: <https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html>. Accessed 7 July 2021.
47. Kroenke K, Spitzer RL, Williams JBW. The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms. *Psychosom Med* **2002**; 64:258–266.
48. CDC. Healthcare workers. 2021. Available at: <https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-index.html>. Accessed 25 January 2022.
49. Headquarters WHO. A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021. World Health Organization, 2021. Available at: https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1. Accessed 25 January 2022.
50. Luo YR, Yun C, Chakraborty I, Wu AHB, Lynch KL. A SARS-CoV-2 Label-Free Surrogate Virus Neutralization Test and a Longitudinal Study of Antibody Characteristics in COVID-19 Patients. *J Clin Microbiol* **2021**; 59:e0019321.
51. Tarke A, Sidney J, Kidd CK, et al. Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases. *Cell Rep Med* **2021**; 2:100204.
52. Department of public health. Available at: <https://www.sfdph.org/dph/comupg/oprograms/HIVepiSec/HIVepiSecReports.asp>. Accessed 3 February 2022.

- 13 53. Lu W, Mehraj V, Vyboh K, Cao W, Li T, Routy J-P. CD4:CD8 ratio as a frontier marker for clinical
14 outcome, immune dysfunction and viral reservoir size in virologically suppressed HIV-positive
15 patients. *J Int AIDS Soc* **2015**; 18:20052.
- 16 54. Avelino-Silva VI, Miyaji KT, Mathias A, et al. CD4/CD8 Ratio Predicts Yellow Fever Vaccine-
17 Induced Antibody Titers in Virologically Suppressed HIV-Infected Patients. *J Acquir Immune*
18 *Defic Syndr* **2016**; 71:189–195.
- 19 55. Peluso MJ, Hellmuth J, Chow FC. Central Nervous System Effects of COVID-19 in People with
20 HIV Infection. *Curr HIV/AIDS Rep* **2021**; Available at: [http://dx.doi.org/10.1007/s11904-021-](http://dx.doi.org/10.1007/s11904-021-00582-x)
21 [00582-x](http://dx.doi.org/10.1007/s11904-021-00582-x).
- 22 56. Kingery JR, Safford MM, Martin P, et al. Health Status, Persistent Symptoms, and Effort
23 Intolerance One Year After Acute COVID-19 Infection. *J Gen Intern Med* **2022**; Available at:
24 <http://dx.doi.org/10.1007/s11606-021-07379-z>.
- 25 57. Zandman-Goddard G, Shoenfeld Y. HIV and autoimmunity. *Autoimmun Rev* **2002**; 1:329–337.
- 26 58. Peluso MJ, Chen J, Munter S, et al. Outcomes of immunomodulatory and biologic therapy in
27 people living with HIV. *AIDS* **2020**; 34:1171–1179.
- 28 59. Viroit E, Duclos A, Adelaide L, et al. Autoimmune diseases and HIV infection: A cross-sectional
29 study. *Medicine* **2017**; 96:e5769.
- 30 60. Carrico AW, Cherenack EM, Roach ME, et al. Substance-associated elevations in monocyte
31 activation among methamphetamine users with treated HIV infection. *AIDS* **2018**; 32:767.
- 32 61. Chen LH, Peterson J, Robertson K, Fuchs D, Price R, Spudich S. Past Substance Use Affects
33 Central Nervous System (CNS) Inflammation in Human Immunodeficiency Virus Infection. *Open*
34 *Forum Infect Dis* **2016**; 3. Available at:

35 https://academic.oup.com/ofid/article/3/suppl_1/853/2637697. Accessed 9 April 2021.

36 62. Frydrych LM, Bian G, O'Lone DE, Ward PA, Delano MJ. Obesity and type 2 diabetes mellitus
37 drive immune dysfunction, infection development, and sepsis mortality. *J Leukoc Biol* **2018**;
38 104:525–534.

39 63. Popkin BM, Du S, Green WD, et al. Individuals with obesity and COVID-19: A global perspective
40 on the epidemiology and biological relationships. *Obes Rev* **2020**; 21:e13128.

41 64. Apicella M, Campopiano MC, Mantuano M, Mazoni L, Coppelli A, Del Prato S. COVID-19 in
42 people with diabetes: understanding the reasons for worse outcomes. *Lancet Diabetes*
43 *Endocrinol* **2020**; 8:782–792.

44 65. New amfAR grants target intersection of HIV and COVID-19. Available at:
45 <https://www.amfar.org/amfAR-Grants-Target-Intersection-of-HIV-and-COVID-19/>. Accessed 26
46 March 2021.

47 66. Choi B, Choudhary MC, Regan J, et al. Persistence and Evolution of SARS-CoV-2 in an
48 Immunocompromised Host. *N Engl J Med* **2020**; 383:2291–2293.

49 67. Cele S, Karim F, Lustig G, et al. SARS-CoV-2 prolonged infection during advanced HIV disease
50 evolves extensive immune escape. *Cell Host Microbe* **2022**; Available at:
51 <https://www.sciencedirect.com/science/article/pii/S1931312822000415>.

52 68. Verburgh ML, Boyd A, Wit FWNM, et al. Similar risk of SARS-CoV-2 infection and similar
53 nucleocapsid antibody levels in people with well-controlled HIV and a comparable cohort of
54 people without HIV. *J Infect Dis* **2021**; Available at: <http://dx.doi.org/10.1093/infdis/jiab616>.

55 69. Martín-Vicente M, Berenguer J, Muñoz-Gómez MJ, et al. Similar humoral immune responses
56 against the SARS-CoV-2 spike protein in HIV and non-HIV individuals after COVID-19. *J Infect*

57 **2021**; Available at: <http://dx.doi.org/10.1016/j.jinf.2021.11.002>.

58 70. Snyman J, Hwa S-H, Krause R, et al. Similar antibody responses against SARS-CoV-2 in HIV
59 uninfected and infected individuals on antiretroviral therapy during the first South African infection
60 wave. *Clin Infect Dis* **2021**; Available at: <http://dx.doi.org/10.1093/cid/ciab758>.

61 71. Spinelli MA, Peluso MJ, Lynch KL, et al. Differences in Post-mRNA Vaccination SARS-CoV-2
62 IgG Concentrations and Surrogate Virus Neutralization Test Response by HIV Status and Type
63 of Vaccine: a Matched Case-Control Observational Study. *Clin Infect Dis* **2021**; Available at:
64 <http://dx.doi.org/10.1093/cid/ciab1009>.

65 72. Gras L, May M, Ryder LP, et al. Determinants of Restoration of CD4 and CD8 Cell Counts and
66 Their Ratio in HIV-1-Positive Individuals With Sustained Virological Suppression on Antiretroviral
67 Therapy. *J Acquir Immune Defic Syndr* **2019**; 80:292–300.





68 73. Sachdev D, Mara E, Hsu L, et al. COVID-19 Susceptibility and Outcomes Among People Living
69 With HIV in San Francisco. *J Acquir Immune Defic Syndr* **2021**; 86:19–21.







Characteristic	All (n=82)	HIV+ (n=39)	HIV- (n=43)
Demographic characteristics			
Age	52 (44-58)	54 (46-58)	51 (43-58)
Sex assigned at birth, n (%)			
Female	10 (12)	2 (5)	8 (19)
Male	72 (88)	37 (95)	35 (81)
Race and ethnicity, n (%)			
Hispanic/Latino	26 (32)	14 (36)	9 (21)
White	36 (43)	15 (38)	25 (60)
Black/African American	(10)	7 (18)	1 (2)
Asian	4 (5)	1 (3)	3 (7)
Pacific Islander/Native Hawaiian	3 (4)	2 (5)	1 (2)
Not Provided	1 (1)	0 (0)	1 (2)
Tobacco use history, n (%)			
Ever smoker	28 (34)	21 (54)	7 (16)
Current smoker	11 (13)	10 (26)	1 (2)
Clinical characteristics			
Concurrent medical conditions, n (%)			
Autoimmune disease*	2 (2)	1 (3)	1 (2)
Cancer (with treatment received within 2 years prior to COVID-19 diagnosis)	4 (5)	3 (8)	1 (2)
Diabetes	7 (9)	4 (10)	3 (7)
Heart disease	4 (5)	4 (10)	0 (0)
Pulmonary disease	8 (10)	5 (13)	3 (7)
HIV-related laboratory parameters			
CD4+ T cell count (cells/uL)	639 (486-844)	596 (404-740)	670 (594-918)
CD4/CD8 ratio	1.18 (0.78-1.86)	0.94 (0.51-1.10)	2.00 (1.52-2.32)
Plasma HIV RNA <50 copies/mL, n (%)	-	37 (95)	-
Body mass index	28.1 (24.8-31.0)	28.8 (25.1-32.5)	27.1 (23.9-30.3)
Hospitalized during acute COVID-19, n (%)	11 (14)	4 (10)	7 (17)
Time since COVID-19 symptom onset (days)	112 (91-129)	118 (85-129)	111 (94-131)

Table 1. Characteristics of study cohort. Values reported as median (IQR) unless otherwise specified. IQR, interquartile range. Note: Autoimmune disease reported as one case of hypothyroidism and one case of Raynaud's disease. Cancer reported as prostate cancer controlled with hormone therapy, ocular melanoma, treated Kaposi sarcoma, and resected renal cancer. Plasma HIV RNA values were >50 in two participants (87 copies/mL and 28,118 copies/mL). All hospitalized participants in each group required oxygen support and one hospitalized participant in each group required mechanical ventilation. None reported receiving SARS-CoV-2-targeted therapy or steroids during the hospitalization.

Symptoms reported at late follow-up	All (n=82)	HIV+ (n=39)	HIV- (n=43)
Constitutional			
<i>Fatigue</i>	26 (32)	16 (42)	10 (23)
<i>Subjective fever</i>	1 (1)	1 (3)	0 (0)
<i>Chills</i>	2 (2)	2 (5)	0 (0)
<i>Objective fever</i>	0 (0)	0 (0)	0 (0)
Upper Respiratory			
<i>Rhinorrhea</i>	13 (16)	5 (13)	8 (19)
<i>Sore throat</i>	2 (2)	0 (0)	2 (5)
Cardiopulmonary			
<i>Cough</i>	7 (9)	3 (8)	4 (9)
<i>Shortness of breath</i>	20 (25)	11 (29)	9 (21)
<i>Chest pain</i>	7 (9)	3 (8)	4 (9)
<i>Palpitations</i>	10 (12)	4 (11)	6 (14)
<i>Fainting</i>	0 (0)	0 (0)	0 (0)
Gastrointestinal			
<i>Diarrhea</i>	7 (9)	5 (13)	2 (5)
<i>Nausea</i>	9 (11)	5 (13)	4 (9)
<i>Loss of appetite</i>	4 (5)	3 (8)	1 (2)
<i>Abdominal pain</i>	9 (11)	5 (13)	4 (9)
<i>Vomiting</i>	1 (1)	0 (0)	1 (2)
<i>Constipation</i>	0 (0)	0 (0)	0 (0)
Genitourinary			
<i>Menstrual cramps</i>	0 (0)	0 (0)	0 (0)
<i>Dyspareunia</i>	0 (0)	0 (0)	0 (0)
Rash	8 (10)	7 (18)	1 (2)
Musculoskeletal			
<i>Myalgia</i>	14 (17)	9 (24)	5 (12)
<i>Back pain</i>	5 (6)	5 (13)	0 (0)
<i>Joint pain</i>	11 (14)	8 (21)	3 (7)
Anosmia/Dysgeusia	14 (17)		
Neurologic			
<i>Headache</i>	14 (17)	9 (24)	5 (12)
<i>Concentration problems</i>	24 (30)	16 (42)	8 (19)
<i>Dizziness</i>	11 (14)	5 (13)	6 (14)
<i>Balance problems</i>	9 (11)	6 (16)	3 (7)
<i>Neuropathy</i>	9 (11)	7 (18)	2 (5)
<i>Vision problems</i>	11 (14)	8 (21)	3 (7)
<i>Parosmia</i>	2 (2)	0 (0)	2 (5)
Trouble Sleeping	20 (24)	13 (34)	7 (16)

Table 2. Symptoms reported at late follow-up among those with PASC. Values reported as n (%). Participants were systematically asked about 32 individual symptoms at the late follow-up visit, which took place a median of 124 days from initial COVID-19 symptom onset.





medRxiv preprint doi: <https://doi.org/10.1101/2022.02.10.22270471>; this version posted February 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

